GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...

You did it to yourself.” This is one of the things that patients who are diagnosed with COPD often hear because of the stigma ...

March 27 (Reuters) - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful ...

Use of CT is proven to save lives in patients eligible for lung cancer screening, which includes most patients with COPD, said Barr, professor of medicine and epidemiology at Columbia University ...

The rate of new chronic obstructive pulmonary disease (COPD) cases decreased from 2001 to 2020, although the prevalence of COPD has increased.

Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), ...

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

Patients with respiratory conditions, such as asthma and COPD, are being encouraged to use apps to manage their symptoms.

COPD is a long-term lung disease that makes it hard to breathe after airways become inflamed and narrowed and mucus builds up ...

Quitting smoking and avoiding vaping may be crucial steps in managing COPD, as these habits expose your lungs to irritants that cause further damage. Quitting may slow the disease’s progression and ...